NEW YORK (GenomeWeb) – The US Food and Drug Administration today approved Thermo Fisher Scientific's next-generation sequencing-based companion diagnostic that can analyze alterations in a panel of genes predictive of response across three non-small cell lung cancer treatments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.